CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 120 filers reported holding CONCERT PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $104,000 | +13.0% | 24,763 | +33.7% | 0.00% | – |
| Q1 2021 | $92,000 | -64.2% | 18,528 | -8.8% | 0.00% | – |
| Q4 2020 | $257,000 | +79.7% | 20,322 | +39.6% | 0.00% | – |
| Q3 2020 | $143,000 | +9.2% | 14,555 | +10.6% | 0.00% | – |
| Q2 2020 | $131,000 | +50.6% | 13,165 | +34.4% | 0.00% | – |
| Q1 2020 | $87,000 | +11.5% | 9,799 | +15.8% | 0.00% | – |
| Q4 2019 | $78,000 | -25.0% | 8,464 | -52.7% | 0.00% | – |
| Q3 2019 | $104,000 | -70.5% | 17,893 | -39.3% | 0.00% | – |
| Q2 2019 | $352,000 | -65.3% | 29,500 | -64.9% | 0.00% | -100.0% |
| Q1 2019 | $1,013,000 | +132.3% | 84,017 | +141.4% | 0.00% | – |
| Q4 2018 | $436,000 | -82.6% | 34,799 | -79.5% | 0.00% | -100.0% |
| Q3 2018 | $2,512,000 | +34.4% | 169,388 | +52.4% | 0.00% | 0.0% |
| Q2 2018 | $1,869,000 | +162.9% | 111,127 | +257.0% | 0.00% | – |
| Q1 2018 | $711,000 | -57.2% | 31,126 | -51.6% | 0.00% | -100.0% |
| Q4 2017 | $1,662,000 | +437.9% | 64,281 | +205.9% | 0.00% | – |
| Q3 2017 | $309,000 | +6.9% | 21,012 | +0.9% | 0.00% | – |
| Q2 2017 | $289,000 | -70.0% | 20,834 | -63.2% | 0.00% | -100.0% |
| Q1 2017 | $964,000 | +1.3% | 56,643 | -38.9% | 0.00% | 0.0% |
| Q4 2016 | $952,000 | -35.6% | 92,766 | -36.6% | 0.00% | 0.0% |
| Q3 2016 | $1,478,000 | +52.7% | 146,304 | +69.5% | 0.00% | 0.0% |
| Q2 2016 | $968,000 | +57.7% | 86,335 | +91.1% | 0.00% | – |
| Q1 2016 | $614,000 | -17.3% | 45,170 | +15.1% | 0.00% | -100.0% |
| Q4 2015 | $742,000 | -79.6% | 39,228 | -79.8% | 0.00% | -66.7% |
| Q3 2015 | $3,642,000 | +6521.8% | 194,150 | +5153.0% | 0.00% | – |
| Q2 2015 | $55,000 | -5.2% | 3,696 | -4.7% | 0.00% | – |
| Q1 2015 | $58,000 | +26.1% | 3,880 | +9.4% | 0.00% | – |
| Q4 2014 | $46,000 | -80.0% | 3,545 | -80.6% | 0.00% | – |
| Q3 2014 | $230,000 | -52.7% | 18,265 | -62.1% | 0.00% | – |
| Q2 2014 | $486,000 | -50.8% | 48,216 | -34.3% | 0.00% | -100.0% |
| Q1 2014 | $987,000 | – | 73,401 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,253,000 | $7,097,000 | 0.26% |
| INGALLS & SNYDER LLC | 1,358,573 | $4,280,000 | 0.19% |
| RA Capital Management | 3,033,603 | $9,556,000 | 0.17% |
| Kensington Investment Counsel, LLC | 85,483 | $269,000 | 0.16% |
| Perceptive Advisors | 4,301,282 | $13,548,000 | 0.10% |
| NewEdge Wealth, LLC | 381,326 | $1,201,000 | 0.05% |
| Black Diamond Financial, LLC | 46,000 | $145,000 | 0.05% |
| Birchview Capital, LP | 20,000 | $63,000 | 0.04% |
| XTX Topco Ltd | 14,305 | $45,000 | 0.02% |
| Alyeska Investment Group, L.P. | 548,090 | $1,726,000 | 0.02% |